Skip to main content
SpringerLink
Log in

Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay

  • Original Article
  • Published:
European Biophysics Journal Aims and scope Submit manuscript

Abstract

Human ErbB family of proteins contains four receptor tyrosine kinases (EGFR, Her2, Her3 and Her4) and has been established as a group of attractive druggable targets against diverse cancers. Over the past decades, a variety of ATP-competitive inhibitors have been discovered to target the orthosteric site of EGFR, which, however, would eventually develop acquired drug resistance due to the missense mutations T790M/C797S occurring in orthosteric site. In recent years, a number of forth-generation inhibitors have been successfully designed to overcome the T790M/C797S-induced drug resistance by targeting EGFR allosteric site instead of orthosteric site. Considering that the four proto-oncogenic ErbB kinases share a high conservation in sequence, structure and function, we herein attempted to investigate the binding potency and cross-reactivity of cognate EGFR allosteric inhibitors over noncognate Her2, Her3 and Her4 kinases––they are closely related to gynecological tumors such as ovarian cancer but no allosteric inhibitors have been reported specifically for them to date. A systematic affinity profile of 12 allosteric inhibitors and 4 orthosteric inhibitors to the 4 ErbB kinases was created by integrating dynamics simulations, energetics calculations and biochemical assays, which was then used to derive a systematic inhibitor selectivity profile for EGFR over other three kinases. It is found that allosteric and orthosteric inhibitors exhibit moderate and modest cross-reactivity across the ErbB family, respectively, but the former generally has a higher binding potency than the latter due to the additional energy cost used for inducing kinase conformational change. Moreover, most allosteric inhibitors can be sensitized by Her2 T798M gatekeeper mutation, a counterpart of EGFR T790M gatekeeper mutation that has been previously reported to cause generic drug resistance for orthosteric inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Abdelbaset MS, Abdel-Aziz M, Ramadan M, Abdelrahman MH, Abbas Bukhari SN, Ali TFS, Abuo-Rahma GEA (2019) Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors. Bioorg Med Chem 27:1076–1086

    Article  CAS  PubMed  Google Scholar 

  • Ai X, Sun Y, Wang H, Lu S (2014) A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Amino Acids 46:1635–1648

    Article  CAS  PubMed  Google Scholar 

  • Bai Z, Hou S, Zhang S, Li Z, Zhou P (2017) Targeting self-binding peptides as a novel strategy to regulate protein activity and function: a case study on the proto-oncogene tyrosine protein kinase c-Src. J Chem Inf Model 57:835–845

    Article  CAS  PubMed  Google Scholar 

  • Bayly CI, Cieplak P, Cornell WD, Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem 97:10269–10280

    Article  CAS  Google Scholar 

  • Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY (2019) Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol 30:e75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cui YH, Chen J, Xu T, Tian HL (2015) Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma. Comput Biol Chem 54:57–65

    Article  CAS  PubMed  Google Scholar 

  • Darden T, York D, Pedersen L (1993) Particale mesh Ewald and N.log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092

    Article  CAS  Google Scholar 

  • Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11:905–919

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Genheden S, Ryde U (2010) How to obtain statistically converged MM/GBSA results. J Comput Chem 31:837–846

    CAS  PubMed  Google Scholar 

  • Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449–461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ghorban DL, Madadkar SA, Shafiei A, Mahmoudian M (2004) Flexible ligand docking studies of matrix metalloproteinase inhibitors using Lamarckian genetic algorithm. Daru J Pharm Sci 12:1–10

    Google Scholar 

  • Hamilton EP, Patel MR, Rodon J, Hong DS (2020) Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies. J Clin Oncol 38:TPS3665

    Article  Google Scholar 

  • He X, Hao Y, Liu X, Guan J, Wang L (2021) Noncognate sensitivity to cognate EGFR allosteric inhibitors at molecular level: new uses for old drugs in gynecological tumors. J Chin Chem Soc 69:1–10

    Google Scholar 

  • Hou T, Yu R (2007) Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem 50:1177–1188

    Article  CAS  PubMed  Google Scholar 

  • Hou T, McLaughlin WA, Wang W (2008) Evaluating the potency of HIV-1 protease drugs to combat resistance. Proteins 71:1163–1174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Izadi S, Harris RC, Fenley MO, Onufriev AV (2018) Accuracy comparison of generalized Born models in the calculation of electrostatic binding free energies. J Chem Theory Comput 14:1656–1670

    Article  CAS  PubMed  Google Scholar 

  • Jänne PA (2008) Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumors. Lung Cancer 60:S3–S9

    Article  PubMed  Google Scholar 

  • Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, Jang J, Lelais G, DiDonato M, Bursulaya B, Michellys PY, Epple R, Marsilje TH, McNeill M, Lu W, Harris J, Bender S, Wong KK, Jänne PA, Eck MJ (2016) Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534:129–132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935

    Article  CAS  Google Scholar 

  • Kelley LA, Gardner SP, Sutcliffe MJ (1996) An automated approach for clustering an ensemble of NMR-derived protein structures into conformationally related subfamilies. Protein Eng 9:1063–1065

    Article  CAS  PubMed  Google Scholar 

  • Kong LL, Ma R, Yao MY, Yan XE, Zhu SJ, Zhao P, Yun CH (2017) Structural pharmacological studies on EGFR T790M/C797S. Biochem Biophys Res Commun 488:266–272

    Article  CAS  PubMed  Google Scholar 

  • Landi L, Cappuzzo F (2013) Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res 2:40–49

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li M, Guo J (2021) Deciphering the T790M/L858R-selective inhibition mechanism of an allosteric inhibitor of EGFR: insights from molecular simulations. ACS Chem Neurosci 12:462–472

    Article  CAS  PubMed  Google Scholar 

  • Li Z, Yan F, Miao Q, Meng Y, Wen L, Jiang Q, Zhou P (2019a) Self-binding peptides: binding-upon-folding versus folding-upon-binding. J Theor Biol 469:25–34

    Article  CAS  PubMed  Google Scholar 

  • Li Z, Miao Q, Yan F, Meng Y, Zhou P (2019b) Machine learning in quantitative protein–peptide affinity prediction: implications for therapeutic peptide design. Curr Drug Metab 20:170–176

    Article  CAS  PubMed  Google Scholar 

  • Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10–18

    CAS  PubMed  PubMed Central  Google Scholar 

  • Madeswaran A, Asokkumar K (2015) Evaluation of inhibitory affinity potential of the alkaloids against crystal structure of human angiotensin-converting enzyme using Lamarckian genetic algorithm. Orient Pharm Exp Med 15:183–189

    Article  Google Scholar 

  • Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C (2015) ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput 11:3696–3713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meher BR, Wang Y (2012) Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies. J Phys Chem B 116:1884–1900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meng X, Li Y, Tang H, Mao W, Yang H, Wang X, Ding X, Xie S (2016) Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids 48:487–497

    Article  CAS  PubMed  Google Scholar 

  • Miller BR, McGee TD, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8:3314–3321

    Article  CAS  PubMed  Google Scholar 

  • Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639–1662

    Article  CAS  Google Scholar 

  • Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ni D, Li Y, Qiu Y, Pu J, Lu S, Zhang J (2020) Combining allosteric and orthosteric drugs to overcome drug resistance. Trends Pharmacol Sci 41:336–348

    Article  CAS  PubMed  Google Scholar 

  • Ning X, Ren X, Xie X, Yan P, Wang D, Huang X (2020) A caffeic acid phenethyl ester analog inhibits the proliferation of nasopharyngeal carcinoma cells via targeting epidermal growth factor receptor. J Biochem Mol Toxicol 34:e22491

    Article  CAS  PubMed  Google Scholar 

  • Palmieri L, Rastelli G (2013) αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discov Today 18:407–414

    Article  CAS  PubMed  Google Scholar 

  • Peng YH, Shiao HY, Tu CH, Liu PM, Hsu JT, Amancha PK, Wu JS, Coumar MS, Chen CH, Wang SY, Lin WH, Sun HY, Chao YS, Lyu PC, Hsieh HP, Wu SY (2013) Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. J Med Chem 56:3889–3903

    Article  CAS  PubMed  Google Scholar 

  • Puigserver P (2018) Signaling transduction and metabolomics. Hematology 7:68–78

    Article  Google Scholar 

  • Robert X, Gouet P (2014) Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42:W320–W324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roskoski R (2019) Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 139:395–411

    Article  CAS  PubMed  Google Scholar 

  • Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327–341

    Article  CAS  Google Scholar 

  • Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M (2015) PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res 4:W443–W447

    Article  CAS  Google Scholar 

  • Santos EDS, Nogueira KAB, Fernandes LCC, Martins JRP, Reis AVF, Neto JBV, Júnior IJDS, Pessoa C, Petrilli R, Eloy JO (2021) EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm 592:120082

    Article  CAS  PubMed  Google Scholar 

  • Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539

    Article  PubMed  PubMed Central  Google Scholar 

  • Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272

    Article  CAS  PubMed  Google Scholar 

  • Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A (2008) Protein levels and gene expressions of the epidermal growth factor receptors, Her1, Her2, Her3 and Her4 in benign and malignant ovarian tumors. Int J Oncol 33:195–204

    CAS  PubMed  Google Scholar 

  • Sun H, Duan L, Chen F, Liu H, Wang Z, Pan P, Zhu F, Zhang JZH, Hou T (2018) Assessing the performance of MM/PBSA and MM/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. Phys Chem Chem Phys 20:14450–14460

    Article  CAS  PubMed  Google Scholar 

  • Tripathi SK, Biswal BK (2021) Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discov Today 26:1466–1472

    Article  CAS  PubMed  Google Scholar 

  • UniProt C (2017) UniProt: the universal protein knowledgebase. Nucleic Acids Res 45:D158–D169

    Article  CAS  Google Scholar 

  • Wan S, Yan R, Jiang Y, Li Z, Zhang J, Wu X (2019) Insight into binding mechanisms of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations. J Biomol Struct Dyn 37:4384–4394

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Wang W, Huo S, Lee M, Kollman PA (2001) Solvation model based on weighted solvent accessible surface area. J Phys Chem B 105:5055–5067

    Article  CAS  Google Scholar 

  • Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174

    Article  CAS  PubMed  Google Scholar 

  • Wang S, Song Y, Liu D (2017) EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett 385:51–54

    Article  CAS  PubMed  Google Scholar 

  • Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T (2018) SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46:W296–W303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17:38

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Xu G, Abad MC, Connolly PJ, Neeper MP, Struble GT, Springer BA, Emanuel SL, Pandey N, Gruninger RH, Adams M, Moreno-Mazza S, Fuentes-Pesquera AR, Middleton SA (2008) 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors. Bioorg Med Chem Lett 18:4615–4619

    Article  CAS  PubMed  Google Scholar 

  • Yoshizawa T, Uchibori K, Araki M, Matsumoto S, Ma B, Kanada R, Seto Y, Oh-Hara T, Koike S, Ariyasu R, Kitazono S, Ninomiya H, Takeuchi K, Yanagitani N, Takagi S, Kishi K, Fujita N, Okuno Y, Nishio M, Katayama R (2021) Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity. NPJ Precis Oncol 5:32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu H, Zhou P, Deng M, Shang Z (2014) Indirect readout in protein–peptide recognition: a different story from classical biomolecular recognition. J Chem Inf Model 54:2022–2032

    Article  CAS  PubMed  Google Scholar 

  • Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070–2075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang Q, Jing T, Cui X, Zhao L (2020) Rational molecular profiling of receptor-associated late transducer peptide selectivity across Her/Rtk kinases. Int J Pept Res Ther 27:1945–1951

    Article  CAS  Google Scholar 

  • Zhang D, Wu H, Zhao J (2021) Computational design and experimental substantiation of conformationally constrained peptides from the complex interfaces of transcriptional enhanced associate domains with their cofactors in gastric cancer. Comput Biol Chem 94:107569

    Article  CAS  PubMed  Google Scholar 

  • Zhao Y, Jiao Y, Sun F, Liu X (2018) Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer. Med Chem Res 27:2160–2170

    Article  CAS  Google Scholar 

  • Zhao Y, Zhu D, Gao J (2021) Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non-small cell lung cancer. J Chin Chem Soc 68:2021–2034

    Article  CAS  Google Scholar 

  • Zhou P, Miao Q, Yan F, Li Z, Jiang Q, Wen L, Meng Y (2019) Is protein context responsible for peptide-mediated interactions? Mol Omics 15:280–295

    Article  CAS  PubMed  Google Scholar 

  • Zhou P, Yan F, Miao Q, Chen Z, Wang H (2021a) Why the first self-binding peptide of human c-Src kinase does not contain class II motif but can bind to its cognate Src homology 3 domain in class II mode? J Biomol Struct Dyn 39:310–318

    Article  CAS  PubMed  Google Scholar 

  • Zhou P, Wang H, Chen Z, Liu Q (2021b) Context contribution to the intermolecular recognition of human ACE2-derived peptides by SARS-CoV-2 spike protein: implications for improving the peptide affinity but not altering the peptide specificity by optimizing indirect readout. Mol Omics 17:86–94

    Article  CAS  PubMed  Google Scholar 

  • Zhou P, Liu Q, Wu T, Miao Q, Shang S, Wang H, Chen Z, Wang S, Wang H (2021c) Systematic comparison and comprehensive evaluation of 80 amino acid descriptors in peptide QSAR modeling. J Chem Inf Model 61:1718–1731

    Article  CAS  PubMed  Google Scholar 

  • Zhu SJ, Zhao P, Yang J, Ma R, Yan XE, Yang SY, Yang JW, Yun CH (2018) Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget 9:13652–13665

    Article  PubMed  PubMed Central  Google Scholar 

  • Zuo X, Zhao H, Li D (2021) Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: molecular implications for ovarian cancer personalized therapy. J Mol Recog 34:e2891

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the CCH foundation.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Cangzhou Central Hospital, Hebei Medical University, Cangzhou, 061000, China

    Yanli Ma, Meiying Ning, Lijuan Zhang, Zeyu An & Jing Zhao

  2. Department of Gynaecology, Cangzhou Central Hospital, Hebei Medical University, Cangzhou, 061000, China

    Bingli Qi

Authors
  1. Yanli Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bingli Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meiying Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lijuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeyu An
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Zhao.

Ethics declarations

Conflict of interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, Y., Qi, B., Ning, M. et al. Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay. Eur Biophys J 51, 283–295 (2022). https://doi.org/10.1007/s00249-022-01594-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00249-022-01594-0

Keywords

Search

Navigation